CN110237118A - The composition of niacinamide-containing mononucleotide is in the application of anti-aging drug/health care product - Google Patents
The composition of niacinamide-containing mononucleotide is in the application of anti-aging drug/health care product Download PDFInfo
- Publication number
- CN110237118A CN110237118A CN201910500376.1A CN201910500376A CN110237118A CN 110237118 A CN110237118 A CN 110237118A CN 201910500376 A CN201910500376 A CN 201910500376A CN 110237118 A CN110237118 A CN 110237118A
- Authority
- CN
- China
- Prior art keywords
- product
- composition
- preparation
- aging
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 42
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 229940079593 drug Drugs 0.000 title claims abstract description 18
- 230000036541 health Effects 0.000 title claims abstract description 18
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 229960003966 nicotinamide Drugs 0.000 title claims abstract description 14
- 235000005152 nicotinamide Nutrition 0.000 title claims abstract description 14
- 239000011570 nicotinamide Substances 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 31
- DAYLJWODMCOQEW-TURQNECASA-O NMN(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-O 0.000 claims description 48
- 241000208340 Araliaceae Species 0.000 claims description 25
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 25
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 25
- 235000008434 ginseng Nutrition 0.000 claims description 25
- 238000003756 stirring Methods 0.000 claims description 25
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims description 23
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims description 23
- 239000009636 Huang Qi Substances 0.000 claims description 22
- 229920001282 polysaccharide Polymers 0.000 claims description 19
- 239000005017 polysaccharide Substances 0.000 claims description 19
- 150000004676 glycans Chemical class 0.000 claims description 18
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 claims description 14
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 14
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 13
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 229930182494 ginsenoside Natural products 0.000 claims description 9
- 229940089161 ginsenoside Drugs 0.000 claims description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 239000005515 coenzyme Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 241000208688 Eucommia Species 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000006201 parenteral dosage form Substances 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- 230000007812 deficiency Effects 0.000 abstract description 7
- 231100001261 hazardous Toxicity 0.000 abstract description 7
- 230000006378 damage Effects 0.000 abstract description 6
- 239000004615 ingredient Substances 0.000 abstract description 4
- 206010067482 No adverse event Diseases 0.000 abstract description 3
- 239000000470 constituent Substances 0.000 abstract description 3
- 230000011506 response to oxidative stress Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 2
- 238000012827 research and development Methods 0.000 abstract description 2
- 230000037149 energy metabolism Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 29
- 230000000694 effects Effects 0.000 description 14
- 230000029058 respiratory gaseous exchange Effects 0.000 description 7
- 238000005265 energy consumption Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 101100102907 Mus musculus Wdtc1 gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- -1 cyclopentadienyl polysaccharide Chemical class 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 229940095686 granule product Drugs 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 238000004900 laundering Methods 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 229940095674 pellet product Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the compositions of drug, health care product research and development field more particularly to niacinamide-containing mononucleotide in the application of anti-aging drug/health care product.The present invention provides a kind of composition, the present invention also provides a kind of preparation method of above-mentioned composition, a kind of application of the product obtained the present invention also provides above-mentioned composition or above-mentioned preparation method in anti-aging drug and/or health care product.In the present invention, NMN can play the role of activating human body energy metabolism and improve body response to oxidative stress, meanwhile, cooperate with the synergistic effect of remaining component, plays good anti-aging effects；Also, each constituent structure in composition is stablized, and is not susceptible to rotten damage after corresponding product is made, meanwhile, each ingredient safety has no adverse reaction substantially to human body；It solves in the prior art, there is be difficult to take into account good anti-aging effects, technological deficiency non-hazardous to human body and stable product quality for anti-aging product.
Description
Technical field
The invention belongs to the compositions of drug, health care product research and development field more particularly to niacinamide-containing mononucleotide anti-ageing
The application of old drug/health care product.
Background technique
With the continuous improvement of people's living standards, the hope that people pursue good health and a long life is also more more and more intense.However it declines
The always inexorable law in any life process, is biology rule independent of man's will, but anti-aging speed,
The service life of people is allowed to reach what the maximum life span of nature imparting was possible to reach.So far, about the theory of Aging mechanism and
Assuming that have it is hundreds of, for example free radical theory, immunity function degeneration theory, neuroendocrine theory, protein synthesize mistake
Accumulation theory etc., and the gene regulation theory, the DNA damage prosthetics that are proposed in recent years based on molecular level and gene level
It says, injury of mitochondria theory, Telomerase theory etc..
In the prior art, although the research of mechanism of resisting senility is varied, the product for being applied to anti-aging is actually rare,
Anti-aging product majority on the market is the extract combination of food or Chinese medicine into a certain extent with enhancing human body at present
The effect of function, but using effect is unsatisfactory, anti-aging effects have to be strengthened.Certain anti-ageing product some are in order to reach very
It is industrial components that good anti-aging effects have used inoxidizability strong, quick in short-term, but harm to the human body is used for a long time
Greatly；The anti-ageing product addition vitamins antioxidant having, but this kind of product stability is poor.
Therefore, the composition of niacinamide-containing mononucleotide is developed in the application of anti-aging drug/health care product, for solving
In the prior art, there is be difficult to take into account good anti-aging effects, and stable product quality non-hazardous to human body for anti-aging product
Technological deficiency, become those skilled in the art's urgent problem to be solved.
Summary of the invention
It is answered in view of this, the present invention provides the compositions of niacinamide-containing mononucleotide in anti-aging drug/health care product
With for solving in the prior art, there is be difficult to take into account good anti-aging effects, and production non-hazardous to human body for anti-aging product
The stable technological deficiency of quality.
The present invention provides a kind of composition, the raw material of the composition include: nicotinamide mononucleotide, Radix Astragali, ginseng,
Ginsenoside Rb1, Co-Q10, Puerarin, folium cortex eucommiae and Huang Mao polysaccharide.
Preferably, in terms of mass parts, the raw material of the composition includes: 1~10 part of nicotinamide mononucleotide, 1~10 part
Radix Astragali, 1~10 part of ginseng, 1~10 part of ginsenoside Rb1,1~10 part of Co-Q10,1~10 part of Puerarin, 1~10 part of Cortex Eucommiae
Leaf and 1~10 part of yellow luxuriant polysaccharide.
Preferably, in terms of mass parts, the raw material of the composition includes 2~8 parts of nicotinamide mononucleotides, 5~7 parts of Huangs
Stilbene, 2~5 parts of ginsengs, 3~6 parts of ginsenoside Rb1s, 1~5 part of Co-Q10,6~9 parts of Puerarins, 2~5 parts of folium cortex eucommiaes and 4
~10 parts of yellow luxuriant polysaccharide
Preferably, the dosage form of the composition are as follows: oral preparation and/or parenteral dosage forms.
Preferably, the oral preparation is selected from: tablet, pulvis, capsule, granule, pill, suspension, syrup, conjunction
Any one or more in agent, powder and dripping pill, the parenteral dosage forms are selected from: injection, inhalant, patch,
The present invention also provides a kind of preparations including one composition of any of the above for any one or more in suppository, paste
Method, the preparation method is that:
Step 1: nicotinamide mononucleotide (NMN), Radix Astragali, ginseng, ginsenoside Rb1, Co-Q10, Puerarin, Cortex Eucommiae
Leaf and Huang Mao polysaccharide are sieved after being separately dried, and are uniformly mixed to obtain the first product；
Step 2: being uniformly mixed after auxiliary material is dry, sieving obtains the second product；
Step 3: heating stir for the second time after stirring for the first time after first product and the second product are dissolved in water,
Preparation obtains product.
Preferably, in step 1, the partial size of the sieving is 60~80 mesh；
In step 2, the partial size of the sieving is 60~80 mesh.
Preferably, in step 2, the auxiliary material is selected from: mannitol, microcrystalline cellulose, magnesium stearate, carboxymethyl cellulose
And any one or more in calcium monohydrogen phosphate.
Preferably, in step 3, the temperature of the first time stirring is 25~40 DEG C, and the temperature of second of stirring is
50 DEG C, the time of second of stirring is 1 hour.
The present invention also provides a kind of including preparation described in one composition of any of the above or any of the above one
Application of the product that method obtains in anti-aging drug and/or health care product.
In conclusion the present invention provides a kind of composition, the raw material of the composition include: nicotinamide mononucleotide,
Radix Astragali, ginseng, ginsenoside Rb1, Co-Q10, Puerarin, folium cortex eucommiae and Huang Mao polysaccharide.The present invention also provides in one kind
The preparation method for stating composition, the product obtained the present invention also provides a kind of above-mentioned composition or above-mentioned preparation method is anti-ageing
Application in old drug and/or health care product.In technical solution provided by the invention, nicotinamide mononucleotide can play activation machine
Body energetic supersession and the effect for improving body response to oxidative stress, meanwhile, cooperate with Radix Astragali, ginseng, ginsenoside Rb1, coenzyme
The synergistic effect of Q10, Puerarin, folium cortex eucommiae and Huang Mao polysaccharide play good anti-aging effects；Also, in composition
Each constituent structure stablize, be made after corresponding product and be not susceptible to rotten damage, meanwhile, each ingredient safety is basic to human body
It has no adverse reaction.The composition of niacinamide-containing mononucleotide provided by the invention is solved in the application of anti-aging drug/health care product
In the prior art, anti-aging product is steady there is being difficult to take into account good anti-aging effects, and product quality non-hazardous to human body
Fixed technological deficiency.
Detailed description of the invention
In order to more clearly explain the embodiment of the invention or the technical proposal in the existing technology, to embodiment or will show below
There is attached drawing needed in technical description to be briefly described, it should be apparent that, the accompanying drawings in the following description is only this
The embodiment of invention for those of ordinary skill in the art without creative efforts, can also basis
The attached drawing of offer obtains other attached drawings.
Fig. 1 is control group, takes tested 6 months periods of NMN group and 1 group of mouse of product, and the result of mouse weight variation is shown
It is intended to (n=10/group)；
Fig. 2 is control group, takes tested 6 months periods of NMN group and 1 group of mouse of product, the result of mouse chow intake
Schematic diagram (n=10/group)；
Fig. 3 is control group, takes tested 6 months periods of NMN group and 1 group of mouse of product, and the result of mouse water intake is shown
It is intended to (n=10/group)；
Fig. 4 is control group, take NMN group and after 1 group of mouse of product tested 6 months, mouse adipose content and lean meat contain
The result schematic diagram (n=10/group) of amount；
Fig. 5 is control group, takes NMN group and after 1 group of mouse of product tested 6 months, the oxygen demand (VO of mouse2) result
Schematic diagram；
Fig. 6 is to take control group, NMN group and after 1 group of mouse of product tested 6 months, the result of mouse energy consumption (EE)
Schematic diagram and breathing entropy (RQ) (n=10/group)；
Fig. 7 is to take control group, NMN group and after 1 group of mouse of product tested 6 months, the result of mouse breathing entropy (RQ) is shown
It is intended to (n=10/group).
Specific embodiment
The present invention provides the compositions of niacinamide-containing mononucleotide in the application of anti-aging drug/health care product, for solving
Certainly in the prior art, anti-aging product is steady there is being difficult to take into account good anti-aging effects, and product quality non-hazardous to human body
Fixed technological deficiency.
The technical scheme in the embodiments of the invention will be clearly and completely described below, it is clear that described implementation
Example is only a part of the embodiment of the present invention, instead of all the embodiments.Based on the embodiments of the present invention, this field is common
Technical staff's every other embodiment obtained without making creative work belongs to the model that the present invention protects
It encloses.
In order to which the present invention is described in more detail, below with reference to embodiment to the group of niacinamide-containing mononucleotide provided by the invention
Object is closed in the application of anti-aging drug/health care product, is specifically described.
The present invention provides a kind of compositions, comprising: nicotinamide mononucleotide (NMN), Radix Astragali, ginseng, ginsenoside
Rb1, Co-Q10, Puerarin, folium cortex eucommiae and Huang Mao polysaccharide.The composition of niacinamide-containing mononucleotide provided by the invention exists
The application of anti-aging drug/health care product, solves in the prior art, and there is be difficult to take into account good anti-aging effect for anti-aging product
Fruit, technological deficiency non-hazardous to human body and stable product quality.
NMN is NAD+Precursor becomes the important coenzyme NAD for participating in many reactions in human body into after cell+.A variety of thin
In born of the same parents' metabolic response, NAD+Key player is all play, is the important support that cell maintains vigour.But with age, NAD+
Level can be reduced constantly, and cellular metabolic activity is also affected therewith.After taking NMN to Aged Mice, it is beneficial to promote it complete
Body metabolism, has positive influence to skeletal muscle, liver function, bone density, eye function, insulin sensitivity, immune function etc.；
After supplementing NMN, facilitates the elderly and maintain cellular energy, alleviate chronic disease symptom related with aging.
Meanwhile in composition provided by the invention, Radix Astragali, ginseng can make Human Cardiomyocytes lactic dehydrogenase and succinic acid de-
Hydrogen enzyme content have it is different degrees of increase, ginseng can be such that in cardiac muscle cell cAMP content increases, and especially sanchinoside E1 has
Promote rabbit cartilage cell proliferation, enhancement of SOD activity, the effect for maintaining II expression of collagen.
Further, the Puerarin in composition can promote the proliferation of osteoblast, differentiation, improve alkaline phosphatase enzyme activity
Property, increase the expression of OPGmRNA；Eucommia leaf extract has facilitation, energy to osteoblastic proliferation and the secretion of ALP zymoprotein
It is apparent to adjust bone metabolism function；Co-Q10 is hydrogen carrier important member and the intermediate link of cell mitochondrial internal respiration chain, energy
Promote ATP to generate, is activator, lipid antioxidant, free radical scavenger and the membrane stabilizer of energetic supersession, is vegetative cell
With the activating agent for improving cell metabolism；Yellow cyclopentadienyl polysaccharide from Chinese medicine Huang slight it is middle extract, it can promote hematopoiesis, there is Immune-enhancing effect and tune
Section effect, and have the effects of enhancing cell metabolism, heart tonifying and anti-aging.
It in technical solution provided by the invention, is specifically matched using specific ingredient, reasonable recipe, compatibility is proper, symbol
Close the theory that traditional Chinese medicine is combined with modern medicine, easy to use, good absorption effect, without bad and toxic side effect；It is tested through clinic
Card can effectively reduce interior free yl, reactive oxygen species be maintained, so as to improve cellular damage caused by electromagnetic radiation of mobile telephone.
Embodiment 1
The present embodiment is the specific embodiment for preparing product 1.
Nicotinamide mononucleotide, Radix Astragali, ginseng, ginsenoside Rb1, Co-Q10, Puerarin, folium cortex eucommiae and Huang Maoduo
Sugar crosses 60~80 meshes after being separately dried, and is uniformly mixed to obtain the first product；
It is uniformly mixed after auxiliary material is dry, crosses 60~80 meshes, obtain the second product；In the present embodiment, auxiliary material is mannitol.
After first product and the second product are dissolved in water, in 25~40 DEG C of progress first time stirrings, heat up after mixing evenly, in
50 DEG C carry out second and stir, and after stirring 1 hour, preparation obtains tablet 1；In the present embodiment, used preparation process is
Conventional formulation technique well known to those skilled in the art, details are not described herein.
In the present embodiment, in the first product, the inventory of each raw material are as follows: 2g nicotinamide mononucleotide, 7g Radix Astragali, 4g people
The yellow luxuriant polysaccharide of ginseng, 1g ginsenoside Rb1,3g Co-Q10,9g Puerarin, 4g folium cortex eucommiae and 7g.
Embodiment 2
The present embodiment is the specific embodiment for preparing product 2.
Nicotinamide mononucleotide, Radix Astragali, ginseng, ginsenoside Rb1, Co-Q10, Puerarin, folium cortex eucommiae and Huang Maoduo
Sugar crosses 60~80 meshes after being separately dried, and is uniformly mixed to obtain the first product；
It is uniformly mixed after auxiliary material is dry, crosses 60~80 meshes, obtain the second product；In the present embodiment, auxiliary material is microcrystalline cellulose
Element.
After first product and the second product are dissolved in water, in 25~40 DEG C of progress first time stirrings, heat up after mixing evenly, in
50 DEG C carry out second and stir, and after stirring 1 hour, preparation obtains pellet product 2；In the present embodiment, used preparation process is
Conventional formulation technique well known to those skilled in the art, details are not described herein.
In the present embodiment, in the first product, the inventory of each raw material are as follows: 10g nicotinamide mononucleotide, 1g Radix Astragali, 2g people
The yellow luxuriant polysaccharide of ginseng, 3g ginsenoside Rb1,10g Co-Q10,1g Puerarin, 2g folium cortex eucommiae and 4g.
Embodiment 3
The present embodiment is the specific embodiment for preparing product 3.
Nicotinamide mononucleotide, Radix Astragali, ginseng, ginsenoside Rb1, Co-Q10, Puerarin, folium cortex eucommiae and Huang Maoduo
Sugar crosses 60~80 meshes after being separately dried, and is uniformly mixed to obtain the first product；
It is uniformly mixed after auxiliary material is dry, crosses 60~80 meshes, obtain the second product；In the present embodiment, auxiliary material is magnesium stearate.
After first product and the second product are dissolved in water, in 25~40 DEG C of progress first time stirrings, heat up after mixing evenly, in
50 DEG C carry out second and stir, and after stirring 1 hour, preparation obtains granule product 3；In the present embodiment, used preparation process
For conventional formulation technique well known to those skilled in the art, details are not described herein.
In the present embodiment, in the first product, the inventory of each raw material are as follows: 8g nicotinamide mononucleotide, 5g Radix Astragali, 10g people
The yellow luxuriant polysaccharide of ginseng, 6g ginsenoside Rb1,1g Co-Q10,10g Puerarin, 5g folium cortex eucommiae and 8g.
Embodiment 4
The present embodiment is the specific embodiment for preparing product 4.
Nicotinamide mononucleotide, Radix Astragali, ginseng, ginsenoside Rb1, Co-Q10, Puerarin, folium cortex eucommiae and Huang Maoduo
Sugar crosses 60~80 meshes after being separately dried, and is uniformly mixed to obtain the first product；
It is uniformly mixed after auxiliary material is dry, crosses 60~80 meshes, obtain the second product；In the present embodiment, auxiliary material is that carboxymethyl is fine
Dimension element.
After first product and the second product are dissolved in water, in 25~40 DEG C of progress first time stirrings, heat up after mixing evenly, in
50 DEG C carry out second and stir, and after stirring 1 hour, preparation obtains capsule product 4；In the present embodiment, used preparation process
For conventional formulation technique well known to those skilled in the art, details are not described herein.
In the present embodiment, in the first product, the inventory of each raw material are as follows: 1g nicotinamide mononucleotide, 10g Radix Astragali, 5g people
The yellow luxuriant polysaccharide of ginseng, 10g ginsenoside Rb1,5g Co-Q10,6g Puerarin, 1g folium cortex eucommiae and 1g.
Embodiment 5
The present embodiment is the specific embodiment for preparing product 5.
Nicotinamide mononucleotide, Radix Astragali, ginseng, ginsenoside Rb1, Co-Q10, Puerarin, folium cortex eucommiae and Huang Maoduo
Sugar crosses 60~80 meshes after being separately dried, and is uniformly mixed to obtain the first product；
It is uniformly mixed after auxiliary material is dry, crosses 60~80 meshes, obtain the second product；In the present embodiment, auxiliary material is calcium monohydrogen phosphate.
After first product and the second product are dissolved in water, in 25~40 DEG C of progress first time stirrings, heat up after mixing evenly, in
50 DEG C carry out second and stir, and after stirring 1 hour, preparation obtains aqua product 5；In the present embodiment, used preparation process is
Conventional formulation technique well known to those skilled in the art, details are not described herein.
In the present embodiment, in the first product, the inventory of each raw material are as follows: 6g nicotinamide mononucleotide, 6g Radix Astragali, 1g people
The yellow luxuriant polysaccharide of ginseng, 4g ginsenoside Rb1,2g Co-Q10,8g Puerarin, 10g folium cortex eucommiae and 10g.
Embodiment 6
The processing of 6.1 animals
Buying the age is 3-4 month C57BL/6 male mices, and all mouse cultivate 2 weeks in animal house adaptability, by 12h
The entrainment illumination in daytime.During cultivation, mouse freely can intake and feed, feeding environment temperature remain 20 DEG C-
22 DEG C, relative humidity 50%-60%.
It was tested after 2 weeks laundering period, mouse is divided into control group, experimental group and NMN composition group: control group
Mouse continues to drink normal water, and experimental mice receives drinking water (the target dose 150mg/ containing product 1 obtained by the present invention
Kg/ days) it is 6 months continuous, the drinking water (target dose is 150mg/kg/ days) that NMN composition group receives the composition containing NMN is continuous
6 months.The same time weekly measures a weight.The intake of continuous 7 days the measurement food and water of every month same time.
6.2 metabolic analysis
Behind 6 months of mouse supplementary 1/NMN, Oxymax indirect calorimetry system is used
(ColumbusInstruments, Columbus, OH) measures metabolizing parameters.Before DATA REASONING, individually it is in temperature by mouse
It 22-24 DEG C, adapts to 24 hours in the environment of 12 hours illumination/12 hour dark cycles.
Oxymax system VO2And VCO2Ratio is provided that 0.7 liter/min of air-flow；0.6 liter/min of sample flow；Timing
Between 5min；Time of measuring 4min.System is calibrated according to correct mixture, measures the O of consumption2(VO2, ml/kg/hr) and produce
Raw CO2(VCO2, ml/kg/hr).
Oxygen demand (VO in assessment 24 hours2) and breathing entropy (VCO2/VO2Ratio).Energy consumption (EE) is according to O2It produces
Raw calorific value (3.815+1.232x breathes entropy) and O2The volume of consumption calculates.
6.3 experimental result
As can be drawn from Figure 1, after supplementing NMN, it can inhibit weight gain caused by mouse increases with age correlation, linearly
Dose-dependent effect all had statistical significance (P < 0.05) 6 months all time points.
As can be drawn from Figure 4, the control group of mouse, NMN group are compared with 1 group of product, standardization weight loss percentage
Average is respectively 4% and 9%；At 6 months, compared with the control group, fat mass is reduced, thin for NMN group and present composition group
Meat amount increases.
Fig. 2 and Fig. 3 are please referred to, with the increase of Mouse Age, compared with control mice, NMN group and 1 group of product of mouse
The consumption of higher levels of food and water can be maintained with dosage-dependent manner；Also, the mouse ratio NMN group that 1 group of product
Body weight increase is faster, more preferably.
During entire experiment, control group, the survival rate no difference of science of statistics between 1 group of mouse group of NMN group and product.?
The notable difference of the cause of death (including urinary obstruction, thrombosis and myocardial infarction) is not observed between each group.Show: this
Product 1 made from the technical solution provided is provided, can be fed in routine by administration aobvious with dosage-dependent manner in mouse
It writes and inhibits age-related weight gain, without there is apparent side effect during entire intervention in 6 months.
6.4 oxygen consumption, energy consumption and breathing entropy measurement
In experimentation, compared with control group mice, the food intake dose of experimental group and NMN group mouse is more, but weight
It is lower.At 6th month, oxygen consumption, energy consumption and the breathing entropy of each group mouse were measured respectively.
It can be concluded that, NMN group and 1 group of product of oxygen demand and energy consumption dramatically increase, and produce from Fig. 5 and Fig. 6
Oxygen demand and energy consumption the ratio NMN group that 1 group of product are higher；As can be drawn from Figure 7,1 group of breathing entropy of NMN group and product significantly drops
It is low.
The above results show: taking the mouse of NMN group and product 1, its main energy sources is converted to rouge from glucose
Fat acid, can further demonstrate that and take NMN group and 1 group of product, have to Mouse Age relevant energetic supersession damage significant pre-
Anti- effect, to play effective anti-aging effects.
Product 2~5 repeats the above-mentioned experiment in the present embodiment, obtains similar experimental result, details are not described herein.
In conclusion the present invention provides a kind of composition, the raw material of the composition include: nicotinamide mononucleotide,
Radix Astragali, ginseng, ginsenoside Rb1, Co-Q10, Puerarin, folium cortex eucommiae and Huang Mao polysaccharide.The present invention also provides in one kind
The preparation method for stating composition, the product obtained the present invention also provides a kind of above-mentioned composition or above-mentioned preparation method is anti-ageing
Application in old drug and/or health care product.In technical solution provided by the invention, nicotinamide mononucleotide can play activation machine
Body energetic supersession and the effect for improving body response to oxidative stress, meanwhile, cooperate with Radix Astragali, ginseng, ginsenoside Rb1, coenzyme
The synergistic effect of Q10, Puerarin, folium cortex eucommiae and Huang Mao polysaccharide play good anti-aging effects；Also, in composition
Each constituent structure stablize, be made after corresponding product and be not susceptible to rotten damage, meanwhile, each ingredient safety is basic to human body
It has no adverse reaction.The composition of niacinamide-containing mononucleotide provided by the invention is solved in the application of anti-aging drug/health care product
In the prior art, anti-aging product is steady there is being difficult to take into account good anti-aging effects, and product quality non-hazardous to human body
Fixed technological deficiency.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also answered
It is considered as protection scope of the present invention.
Claims (10)
1. a kind of composition, which is characterized in that the raw material of the composition includes: nicotinamide mononucleotide, Radix Astragali, ginseng, people
Join saponin(e Rb1, Co-Q10, Puerarin, folium cortex eucommiae and Huang Mao polysaccharide.
2. composition according to claim 1, which is characterized in that in terms of mass parts, the raw material of the composition includes: 1
~10 parts of nicotinamide mononucleotides, 1~10 part of Radix Astragali, 1~10 part of ginseng, 1~10 part of ginsenoside Rb1,1~10 part of coenzyme
The yellow luxuriant polysaccharide of Q10,1~10 part of Puerarin, 1~10 part of folium cortex eucommiae and 1~10 part.
3. composition according to claim 1, which is characterized in that in terms of mass parts, the raw material of the composition includes 2~
8 parts of nicotinamide mononucleotides, 5~7 parts of Radix Astragalis, 2~5 parts of ginsengs, 3~6 parts of ginsenoside Rb1s, 1~5 part of Co-Q10,6~9
Part Puerarin, 2~5 parts of folium cortex eucommiaes and 4~10 parts of yellow luxuriant polysaccharide.
4. the composition to 3 described in any one according to claim 1, which is characterized in that the dosage form of the composition are as follows: oral
Preparation and/or parenteral dosage forms.
5. composition according to claim 4, which is characterized in that the oral preparation is selected from: tablet, pulvis, capsule,
Any one or more in granule, pill, suspension, syrup, mixture, powder and dripping pill, the Parenteral administration
Dosage form is selected from: injection, inhalant, patch, suppository, any one or more in paste.
6. a kind of preparation method including composition described in claim 1 to 5 any one, which is characterized in that the preparation side
Method are as follows:
Step 1: nicotinamide mononucleotide, Radix Astragali, ginseng, ginsenoside Rb1, Co-Q10, Puerarin, folium cortex eucommiae and Huang Mao
Polysaccharide is sieved after being separately dried, and is uniformly mixed to obtain the first product；
Step 2: being uniformly mixed after auxiliary material is dry, sieving obtains the second product；
Step 3: heating stir for the second time after stirring for the first time, preparation after first product and the second product are dissolved in water
Obtain product.
7. preparation method according to claim 6, which is characterized in that in step 1, the partial size of the sieving is 60~80
Mesh；
In step 2, the partial size of the sieving is 60~80 mesh.
8. preparation method according to claim 6, which is characterized in that in step 2, the auxiliary material is selected from: mannitol, micro-
Any one or more in crystalline cellulose, magnesium stearate, carboxymethyl cellulose and calcium monohydrogen phosphate.
9. preparation method according to claim 6, which is characterized in that in step 3, the temperature of the first time stirring is
25~40 DEG C, the temperature of second of stirring is 50 DEG C, and the time of second of stirring is 1 hour.
10. a kind of including preparation described in composition described in claim 1 to 5 any one or claim 6 to 9 any one
Application of the product that method obtains in anti-aging drug and/or health care product.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910500376.1A CN110237118A (en) | 2019-06-06 | 2019-06-06 | The composition of niacinamide-containing mononucleotide is in the application of anti-aging drug/health care product |
| PCT/CN2020/075629 WO2020244250A1 (en) | 2019-06-06 | 2020-02-18 | Use of composition containing nicotinamide mononucleotides in anti-aging drugs/healthcare products |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910500376.1A CN110237118A (en) | 2019-06-06 | 2019-06-06 | The composition of niacinamide-containing mononucleotide is in the application of anti-aging drug/health care product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110237118A true CN110237118A (en) | 2019-09-17 |
Family
ID=67886547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910500376.1A Withdrawn CN110237118A (en) | 2019-06-06 | 2019-06-06 | The composition of niacinamide-containing mononucleotide is in the application of anti-aging drug/health care product |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN110237118A (en) |
| WO (1) | WO2020244250A1 (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111374310A (en) * | 2020-04-16 | 2020-07-07 | 上海益跬尔生物科技有限公司 | Edible compound mitochondrial energy enhancing formula |
| CN111603552A (en) * | 2020-07-02 | 2020-09-01 | 中健智诊(重庆)生物研究院 | Anti-aging composition and application thereof |
| CN111956684A (en) * | 2020-09-07 | 2020-11-20 | 石药集团远大(大连)制药有限公司 | Anti-aging composition and preparation method thereof |
| WO2020244250A1 (en) * | 2019-06-06 | 2020-12-10 | 泓博元生命科技（深圳）有限公司 | Use of composition containing nicotinamide mononucleotides in anti-aging drugs/healthcare products |
| CN112137977A (en) * | 2020-09-28 | 2020-12-29 | 深圳雾件科技有限公司 | Nicotinamide mononucleotide sustained-release enteric orally disintegrating tablet and preparation method thereof |
| CN113350233A (en) * | 2021-05-24 | 2021-09-07 | 上海优康化妆品有限公司 | Anti-aging composition and preparation method and application thereof |
| CN113455651A (en) * | 2021-07-09 | 2021-10-01 | 杨水祥 | A preparation containing stem cell extractive solution for improving metabolism and immunity and improving sub-health |
| WO2022042615A1 (en) * | 2020-08-25 | 2022-03-03 | 大江生医股份有限公司 | Yeast powder rich in nicotinamide mononucleotide, preparation method therefor, and application thereof |
| NL1044087A (en) * | 2020-08-12 | 2022-04-04 | Dr Jelena Barjaktarovic Md | Combination of Vitamin C, red ginseng, nicotinamide mononucleotide (NMN) and resveratrol as a healthy functional food (food supplement)) |
| NL1044089A (en) * | 2020-08-12 | 2022-04-04 | Dr Jelena Barjaktarovic Md | Combination of Vitamin C, red ginseng, nicotinamide mononucleotide (NMN) and resveratrol as a healthy functional food (food supplement)) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100443109C (en) * | 2005-12-16 | 2008-12-17 | 李民主 | Medicament for preventing and treating ageing diseases |
| CN104814974A (en) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | Application of nicotinamide mononucleotide in preparation of anti-aging drugs or health care products |
| CN105935372A (en) * | 2016-04-12 | 2016-09-14 | 宁波立华制药有限公司 | Preparation method of qi-blood Kang oral liquid |
| CN107343891A (en) * | 2016-05-04 | 2017-11-14 | 范臻 | A kind of help medicinal liquor |
| JP6920071B2 (en) * | 2017-02-16 | 2021-08-18 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | Adiponectin secretion improver |
| CN109350557A (en) * | 2018-05-25 | 2019-02-19 | 泓博元生命科技（深圳）有限公司 | Anti-apolexis composition, skin care item comprising NADH and ceramide and the preparation method and application thereof |
| CN110237118A (en) * | 2019-06-06 | 2019-09-17 | 泓博元生命科技（深圳）有限公司 | The composition of niacinamide-containing mononucleotide is in the application of anti-aging drug/health care product |
-
2019
- 2019-06-06 CN CN201910500376.1A patent/CN110237118A/en not_active Withdrawn
-
2020
- 2020-02-18 WO PCT/CN2020/075629 patent/WO2020244250A1/en active Application Filing
Non-Patent Citations (1)
| Title |
|---|
| KATHRYN F. MILLS等: ""Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice"", 《CELL METAB》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020244250A1 (en) * | 2019-06-06 | 2020-12-10 | 泓博元生命科技（深圳）有限公司 | Use of composition containing nicotinamide mononucleotides in anti-aging drugs/healthcare products |
| CN111374310A (en) * | 2020-04-16 | 2020-07-07 | 上海益跬尔生物科技有限公司 | Edible compound mitochondrial energy enhancing formula |
| CN111603552A (en) * | 2020-07-02 | 2020-09-01 | 中健智诊(重庆)生物研究院 | Anti-aging composition and application thereof |
| NL1044087A (en) * | 2020-08-12 | 2022-04-04 | Dr Jelena Barjaktarovic Md | Combination of Vitamin C, red ginseng, nicotinamide mononucleotide (NMN) and resveratrol as a healthy functional food (food supplement)) |
| NL1044089A (en) * | 2020-08-12 | 2022-04-04 | Dr Jelena Barjaktarovic Md | Combination of Vitamin C, red ginseng, nicotinamide mononucleotide (NMN) and resveratrol as a healthy functional food (food supplement)) |
| WO2022042615A1 (en) * | 2020-08-25 | 2022-03-03 | 大江生医股份有限公司 | Yeast powder rich in nicotinamide mononucleotide, preparation method therefor, and application thereof |
| CN111956684A (en) * | 2020-09-07 | 2020-11-20 | 石药集团远大(大连)制药有限公司 | Anti-aging composition and preparation method thereof |
| CN112137977A (en) * | 2020-09-28 | 2020-12-29 | 深圳雾件科技有限公司 | Nicotinamide mononucleotide sustained-release enteric orally disintegrating tablet and preparation method thereof |
| CN113350233A (en) * | 2021-05-24 | 2021-09-07 | 上海优康化妆品有限公司 | Anti-aging composition and preparation method and application thereof |
| CN113455651A (en) * | 2021-07-09 | 2021-10-01 | 杨水祥 | A preparation containing stem cell extractive solution for improving metabolism and immunity and improving sub-health |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020244250A1 (en) | 2020-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110237118A (en) | The composition of niacinamide-containing mononucleotide is in the application of anti-aging drug/health care product | |
| CN103609944B (en) | Blood pressure reducing and sleeping promoting health-care food | |
| CN105475965A (en) | Biological health care salt and preparation method thereof | |
| CN101991019A (en) | Traditional Chinese medicine chicken feed and production method of silky fowl egg capable of tonifying kidney, strengthening yang and resisting fatigue | |
| CN104489409A (en) | Experimental macaque feed and feeding method thereof | |
| CN110151715A (en) | A kind of Biocal and preparation method thereof that lactating female is applicable | |
| CN109602019A (en) | A kind of probiotic food and preparation method thereof with reduction body fat content function | |
| CN107821713A (en) | Collagen mineral complex pressed candy | |
| CN102919014A (en) | Cultivation method of micronutrient enriched wheat | |
| CN107647158A (en) | A kind of egg feedstuff for reducing Egg cholesterol amount and preparation method thereof | |
| CN101224202A (en) | Weight reducing compound | |
| CN101690591A (en) | Yak marrow polypeptide bone growing and height increasing tablets (powder) | |
| CN105495594A (en) | Nutrition powder beneficial to child bone growth and development and preparation method thereof | |
| Lim et al. | Anti-diabetic effect of material fermented using rice bran and soybean as the main ingredient by Bacillus sp. | |
| CN103859290A (en) | Kelp and mung bean healthcare steamed bun and preparation method thereof | |
| CN101218978A (en) | Protein powder added cucumber seed powder | |
| JP2004149471A (en) | Hypoglycemic agent | |
| CN102925594B (en) | High sweetness zero calorie sucrose | |
| CN101496571A (en) | Burdock ultramicro powder and method for preparing solid beverage thereof | |
| CN104161185A (en) | Nutritional feed additive for livestock and poultry, preparation method thereof and application thereof | |
| CN102919847B (en) | Nutrient rice noodles capable of preventing osteoporosis and preparation method of same | |
| TWI584812B (en) | Mitochondria regulator in a cell | |
| CN108576474A (en) | Improve the feed addictive of laying hen egg quality | |
| CN105341372A (en) | Beef cattle nutritional agent and preparation method thereof | |
| CN103656624A (en) | Compound silkworm pupa hypoglycemic health-care medicinal composition as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190917 |
|
| WW01 | Invention patent application withdrawn after publication |